Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could one pill a day keep the transplant safe?

NCT ID NCT06354179

Disease control Sponsor: University Hospital, Limoges Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests whether taking immunosuppressant drugs just once daily after a liver transplant is as safe and effective as the standard twice-daily schedule. The goal is to make it easier for patients to stick with their lifelong medication, which could improve their quality of life. About 162 adult liver transplant recipients will be followed for one year to compare rejection rates, adherence, and side effects between the two dosing strategies.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
tacrolimus and mycophenolate mofetil (immunosuppressants)
What this could lead to
If successful, this could simplify lifelong medication schedules for liver transplant patients, making it easier to stick to treatment and potentially improving quality of life.
What could go wrong
This is a Phase 4 study with 162 participants, so results may not apply to all patients. Simplifying dosing might not improve adherence or could slightly increase rejection risk.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 4

Runs after approval, following long-term safety and how well the treatment works in everyday use.

Participants

About 162 people

The number the study aims to enrol. It can still change while the study runs.

Started

Apr 2025

Expected to finish

Apr 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Recipients of a first liver allograft from a deceased donor * Transplanted for less than four weeks at enrolment. * Without inter-current progressive life-threatening or graft-threatening disease. * Having signed a written informed consent for their participation in the study. * Affiliated to, or beneficiary of, a social security regimen Exclusion Criteria: * Recipients of a split-liver transplantation. * Recipients of any transplanted organ other than the liver * Patient who has undergone colon resection * Patients under legal protection (guardianship, curatorship). * Patient presenting any contra-indication to tacrolimus or to MMF according to the summary of product characteristics (SmPC) of ENVARSUS®, ADVAGRAF® and CELLCEPT®. * Patients in whom everolimus-based calcineurin inhibitors (CNI) minimization is anticipated * Patients treated with HIV or HCV protease inhibitors. * Pregnant or lactating women. * Women of childbearing potential without any effective contraceptive method (according to the guidelines of CTFG, Clinical Trial Facilitation Group, related to contraception and pregnancy test in clinical trials) or not practicing sexual abstinence. * Sexually active men having a female partner, without any effective contraception. * Patients incapable of understanding the purposes and risks of the study, who cannot give written informed consent, or who are unwilling to comply with the study protocol. * Patients enrolled in another clinical study evaluating drugs or therapeutic strategies potentially interfering with the objectives of the EASY study.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Immunosuppression are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

transplant rejection

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Immunosuppression Liver transplantation

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    18 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • APHP

    RECRUITING

    Marseille, 13000, France

  • Beaujon hospital - APHP

    RECRUITING

    Clichy, 92110, France

  • Bordeaux university hospital

    RECRUITING

    Pessac, 33604, France

  • CHU de Besançon - Hôpital Jean Minjoz

    RECRUITING

    Besançon, 25000, France

  • CHU de Dijon Bourgogne

    RECRUITING

    Dijon, 21000, France

  • CHu de Grenoble

    NOT_YET_RECRUITING

    Grenoble, 38043, France

  • Lille university hospital

    RECRUITING

    Lille, 59000, France

  • Limoges university hospital

    RECRUITING

    Limoges, 87042, France

  • Lyon university hospital

    RECRUITING

    Lyon, 69000, France

  • Montpellier university hospital

    RECRUITING

    Montpellier, 34000, France

  • Nice university hospital

    RECRUITING

    Nice, 06202, France

  • Paul Brousse Hospital - APHP

    RECRUITING

    Villejuif, 94800, France

  • Pitie Salpetriere hospital - APHP

    RECRUITING

    Paris, 75013, France

  • Poitiers university hospital

    RECRUITING

    Poitiers, 86000, France

  • Rennes university hospital

    RECRUITING

    Rennes, 35033, France

  • Strasbourg university hospital

    RECRUITING

    Strasbourg, 67000, France

  • Toulouse university hospital

    RECRUITING

    Toulouse, 31000, France

  • Tours university Hospital

    RECRUITING

    Tours, 37000, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.